BEA-17

STOCKHOLM, April 11, 2023 /PRNewswire/ -- Beactica Therapeutics AB, the Swedish precision oncology company, today announced that its LSD1 programme has been selected for a poster presentation at the American Association for Cancer Research's Annual Meeting 2023. The conference will take place on April 14-19, 2023 at the Orange County Convention Center in Orlando, Florida. Dr Konrad Koehler, Head of Discovery, will present a poster entitled Potentiation of Immunotherapy by LSD1 Modulation on Sunday April 16, 2023, at 1:30 PM – 5:00 PM. The location is at the Orange County Convention Center, Section 24, Abstract Presentation Number: 705. The session category is Immunology. Beactica Therapeutics' poster presentation will include new positive results with BEA-17 from in vitro and in vivo studies, including potentiation of anti-PD1 checkpoint inhibitors in a syngeneic animal model of colon cancer (CT26) and potentiation of standard of care (radiation + temozolomide) in a syngeneic animal model of glioblastoma (GL261). BEA-17 was recently granted Orphan Drug Designation by the U.S. Food and Drug Administration (FDA) for the treatment of glioblastoma (GBM). Organised by the American Association for Cancer Research, the AACR Annual Meeting is the largest and most important cancer drug discovery event in the world. It has an anticipated attendance of more than 20 000 scientists, clinicians, advocates, and other attendees. The event spans integrative cancer science, global impact, individualised patient care and showcases the best and most up-to-date cancer science available. About BEA-17 BEA-17 is a first-in-class small molecule targeted degrader (non-PROTAC) of the epigenetic enzyme LSD1 and its co-factor CoREST. The compound has shown promising preclinical in vivo potentiation of immune-modulating treatments in several cancer forms, including anti-PD1 checkpoint inhibitors in syngeneic models of colon cancer (CT26) and standard of care (temozolomide and radiation) in syngeneic models of glioblastoma (GL261). Pharmacokinetic studies of BEA-17 show good blood-brain-barrier penetration and oral availability. BEA-17 is investigational and not approved anywhere globally. Its efficacy and safety in humans have not been established. BEA-17 has been granted Orphan Drug Designation by the U.S. Food and Drug Administration (FDA) for the treatment of glioblastoma (GBM). About Beactica Therapeutics Beactica Therapeutics AB is a privately held precision oncology company committed to the fight against cancer. The company is advancing a pipeline of novel small molecule therapeutics with a focus to treat genetically defined cancers with significant unmet medical need. Beactica's approach is centered around targeting synthetically lethal disease proteins with allosteric modulators and targeted protein degraders (PROTACs). Beactica deliver value to patients and shareholders by advancing its programmes to clinical proof of concept. For more information, please visit . Beactica Therapeutics Contact Per Källblad M.Sc. Ph.D. CEO per.kallblad@beactica.com Tel: +46 18 56 08 80 The following files are available for download: View original content: SOURCE Beactica Therapeutics AB

UPPSALA, Sweden and SEOUL, South Korea, April 4, 2023 /PRNewswire/ -- Beactica Therapeutics AB, the Swedish precision oncology company, and Oscotec Inc. (039200: KOSDAQ), the Korean drug development company, today announced that they have mutually agreed to terminate their collaboration and licensing agreement. The collaboration focused on research and development of novel anti-cancer drug candidates arising out of Beactica's LSD1 programme. The LSD1 programme includes BEA-17, a first-in-class small molecule targeted degrader of the epigenetic enzyme LSD1 and its co-factor CoREST. The current lead indication for BEA-17 is glioblastoma, an indication that falls outside the scope of Oscotec's strategic priorities. As part of the agreement, Beactica Therapeutics will retain full exclusive global rights for further development and commercialization of the LSD1 programme, and gain ownership of all results from the collaboration. No obligations will remain between the companies. BEA-17 was recently granted Orphan Drug Designation by the U.S. Food and Drug Administration (FDA) for the treatment of glioblastoma (GBM). "We have valued the opportunity to collaborate with Beactica Therapeutics and congratulate them on FDA's Orphan Drug Designation to BEA-17 for the treatment of glioblastoma," said Dr Taeyoung Yoon, CEO/CSO of Oscotec. "For portfolio reasons, we have now decided to focus on internal assets that are more closely aligned with our strategic objectives." "We have appreciated the collaboration with Oscotec and are pleased by what we have achieved together. Retaining global rights to the LSD1 programme increases the potential in Beactica and is well aligned with the Company's ambition to itself become a clinical-stage company," said Dr Per Källblad, CEO of Beactica Therapeutics. About Beactica Therapeutics Beactica Therapeutics AB is a privately held precision oncology company committed to the fight against cancer. The company is advancing a pipeline of novel small molecule therapeutics to treat genetically defined cancers with significant unmet medical need. Beactica's approach is centered around targeting synthetically lethal disease proteins with allosteric modulators and targeted protein degraders (PROTACs). Beactica deliver value to patients and shareholders by advancing its programmes to clinical proof of concept. For more information, please visit . About Oscotec Oscotec Inc. (039200: KOSDAQ) is a clinical stage drug discovery and development company. Our mission is to create values by translating cutting edge science into innovative medicine for clinically unmet needs. We focus on discovering small molecules with a novel mechanism of action and validating the drug-target-disease hypothesis through rigorous science into clinical proof-of-concept. We aspire to become a leading "discovery engine" that provides the critical impact in developing transformative therapies that will improve patients' lives. For more information, please visit . Beactica Therapeutics Contact Per Källblad M.Sc. Ph.D. CEO [email protected] Tel: +46 18 56 08 80 Oscotec Contact Jihyun Park, IR/PR [email protected] Phone: +82 316287616 The following files are available for download: SOURCE Beactica AB